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EFFICACY OF Nd: YAG LASER VITREOLYSIS ON SYMPTOMATIC 




Background: Complaints of vitreous floaters are not new to veteran ophthalmologists, 
and many can attest to the reported burden symptomatic floaters have on visual clarity 
and quality of life. Classic treatment paradigms recommend indefinite observation or, in 
the case of severely bothersome floaters, pars plana vitrectomy (PPV). Despite the proven 
efficacy, PPV requires intraocular access and has a side effect profile that warrants severe 
visual impairment to justify the risks of surgery. Floater laser treatment has the potential 
to fill the treatment gap as a less invasive alternative using photodisruption to vaporize 
floaters. Studies have attempted to quantify the efficacy of Nd:YAG laser treatment with 
moderate success, but the safety profile of the laser floater treatment (LFT) is still limited 
in duration of follow-up. 
Objective: To analyze the efficacy and safety of Nd:YAG laser vitreolysis performed in-
clinic as measured by number of sessions, patients who went on to pursue secondary 
vitrectomy, and a self-reported survey comparing visual satisfaction before and after 
LFT.  
Methods: In a retrospective study, 32 eyes with a history of symptomatic floaters of 
varied etiology were treated with the Ellex Nd:YAG laser set to single-shot mode with a 
maximal pulse energy of 7mJ. The number of treatments each patient underwent until 
	
	 	vi	
receiving full visual benefit served as an objective measure of the efficacy of the laser. 
Secondary vitrectomy patients who failed laser vitreolysis were sampled as evidence of 
inadequate response to treatment. A self-administered survey explored patient satisfaction 
in terms of overall quality of vision, frequency/severity of floaters, and impact floaters 
have on activities of daily life (ADLs) before and after the laser, graded on a 4-point 
scale. 
Results: Laser Floater Treatment performed in-clinic at Boston Vision/Boston Laser 
(BVBL) yielded moderate success in resolving symptomatic floaters, as indicated by 
improved mean patient scores following treatment for quality of vision (+1.13), 
frequency/severity of floaters (+1.00), and impact floaters have on ADLs (+1.33) when 
compared to pretreatment scales. The mean number of discrete treatment sessions to 
gleam full benefit of laser vitreolysis was 2.5 sessions per patient. Approximately 6% 
(2/32) patients failed vitreolysis and went on to pursue PPV.  
Conclusions: Our results showed an improvement of mean patient scores in overall 
quality of vision, severity of floaters, and floaters’ impact by at least 1 scale point, 
supporting the efficacy of laser vitreolysis. Patients underwent a mean of 2.5 treatment 
sessions, and offering multiple sessions likely bolstered the overall efficacy of the 
procedure. The sample population of 32 yielded only two patients (6%) who went on to 
pursue secondary vitrectomy, suggesting LFT could potentially serve as another 
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Etiology of Vitreous Floaters 
 
The vitreous is a clear gel filling the posterior chamber of the eye, translucent and 
homogeneous in youth. Its complex biochemical structure consists of hyaluronan and 
collagen fibrils interacting with water molecules and glycoproteins to form a jelly-like 
substance1. Structurally, these components are arranged into lacunae and bursae that 
naturally degrade as we age2. Vitreous synchysis, or the liquefaction of the gel, forms 
pockets of liquid vitreous in lacunae which can also contribute to the manifestation of 
floaters1,3. Vitreous degradation leads to the deposition of collagen fibrils which, once 
present, have the potential to crosslink, exacerbating symptoms and contributing to the 
aggregation, thickening, and proliferation of these collagen masses.  Other risk factors for 
developing floaters include retinal injuries, trauma, and intraocular inflammation4. The 
most common ocular disease leading to symptomatic floaters is posterior vitreous 
detachment (PVD), primarily affecting patients of advanced age (greater than 50 years 
old). PVD occurs as a result of vitreous syneresis or the compaction of the jelly-like 
substance. As the jelly loses structural integrity over time, the hyaloid face of the 
posterior vitreous pulls away from the retina, producing symptomatic floaters. Often, 
ophthalmologists will monitor the vitreal detachment throughout a patient’s life without 
pursuing intervention5. This degenerative process is accelerated in myopes due to the 




ring, or a characteristic circular floater resulting from fibroglial tissue formerly 
surrounding the optic nerve. Weiss rings are generally good targets for vitreolysis due to 
their discrete borders and visualization6,7. Pathological or not, vitreous floaters impede 
visual clarity necessary for daily activities such as reading, computer work, driving, and 
exercise, potentially affecting patients’ vision for the duration of their life. As a result, 
symptomatic patients seek an intervention that can provide unobstructed vision without 
risking blindness and other complications inherent with surgery. Successful floater 
removal therapies have proven to drastically improve quality of life, reinforcing the 
importance of developing an effective, safe treatment for symptomatic floaters7,8.  
 
Vitreous Floaters in the Ophthalmic Setting 
Symptomatic floaters comprise many complaints heard in the ophthalmic setting 
due to their ubiquity and benign nature. Their commonality can be attributed to the wide 
range of etiology ranging from natural aging to pathological retinal events. “Floaters'' 
result from opacities casting shadows on the retina; these opacities are usually the result 
of natural vitreous changes, but blood, inflammation, and debris can produce identical 
symptomatology9,10. Symptomatic floaters generally exist within the middle and posterior 
vitreous as their proximity casts a darker, more discrete shadow onto the nearby retina. 
Floaters are most evident in high contrast settings or against bright backgrounds, so some 
ophthalmologists use contrast sensitivity as a measure to quantify visual dysfunction 
secondary to floaters11,12. Studies have estimated a 67% decrease in contrast sensitivity in 




patients feel slighted by the lack of treatment options for such a debilitating disease, 
spurring a growing demand for accessible treatment options.  
Majority of patients will develop vitreous floaters within their lifetime but only a 
minority of patients considers their floaters bothersome enough to pursue intervention14. 
Standard of treatment for floaters in the ophthalmic setting is observation; physicians 
generally recommend monitoring symptoms for several months as small, diffuse floaters 
can spontaneously self-resolve by becoming translucent, disintegrating or moving out of 
the visual axis15,16. As the vitreous contracts, opacities can migrate anteriorly, reducing 
the shadow cast onto the retina and thus mitigating symptoms. Patients can also 
neurologically adapt to the visual disturbance, usually resulting in an improvement of 
symptoms without treatment17. Dr. Shah at Ophthalmic Consultants of Boston reports 
that in 99.9% of floater complaints, the preferred treatment course is observation18,19. 
Floaters generally drift in and out of the field of vision but can follow the patient’s gaze, 
making centrally located floaters especially bothersome. They are best visualized through 
a slit lamp examination when patient’s pupil is dilated but can also be seen on optical 
coherence tomography (OCT), B-scan Ultrasound, and OptosAdvance Ultrasound 
Imaging7,20,21,22. 
 
The Visual Burden of Floaters 
In a study of over 600 participants, more than 70% of patients complained of 
floaters in their vision with 33% claiming these floaters drastically impair their vision11. 




developing treatment options for the debilitating disease. The prevalence of floater 
complaints in an ophthalmic setting is projected to increase, partially due to the increase 
in life-expectancy and the global increase in myopia since 2000. Myopic vitreopathy can 
be especially frustrating for patients who develop floaters in their youth and are burdened 
with the accumulation of a lifetime of floaters as they age23.  
To distinguish between asymptomatic and bothersome floaters, Dr. Sebag coined 
the term vision-degrading vitreopathy to describe floaters with moderate to severe effect 
on visual quality13. This minority group of patients, while not at risk for debilitating 
disease progression, reports functional impairment to such a degree that they are 
motivated to risk blindness for a resolution. Wagle and his team developed utility values 
to quantify visual impairment secondary to vitreous floaters. Their study utilized standard 
gamble (SG) for death and blindness, a standard measure based on expected utility 
theory24 used to quantify risk tolerance in determining the burden of illness. Results 
showed mean utility values of 0.89 and 0.93 for SG (death) and SG (blindness), 
respectively. Standard gamble values indicate sampled patients were willing to trade 1.1 
of 10 years of their remaining life for complete resolution of floaters25. In a hypothetical 
scenario, patients accepted an average risk tolerance of 11% for death and 7% for 
blindness for complete resolution of their floaters. These values were comparable with 
degenerative conditions such as age-related macular degeneration (AMD)8. Numerically 
quantifying the visual burden of symptomatic floaters reinforces the functional 




A study conducted by Kim and associates revealed the psychological impact of 
vitreous floaters using subjective data collected from a population of symptomatic 
vitreous floater patients with a history of PVD. Measures included the level of 
depression, perceived stress, and degree of floater-associated discomfort from both 
symptomatic and control groups. Analysis revealed higher psychological distress 
associated with symptomatic floaters, positively correlated to the severity of reported 
floaters26. Functional impairment secondary to vitreous opacities can frustrate patients 
who have attempted to cope unsuccessfully with their visual disturbances, especially in 
response to the current treatment paradigms recommending observation, sometimes 
indefinitely27. Limited 25-gauge PPV can offer a complete resolution of symptoms for 
patients whose impairment affects their quality of life but requires substantial visual 
dysfunction to warrant the risks of intraocular surgery28. Patients experiencing 
diminished visual clarity affecting their daily life can benefit immensely if floater laser 
treatment is proven to be efficacious with a safe side effect profile.  
 
The Ellex Laser and Lens Optics 
Vitreolysis can be performed using any existing YAG laser commonly found in 
ophthalmology clinics for selective laser trabeculoplasty (SLT), capsulotomy and 
iridotomy procedures29, but the existing machinery is not optimal for vitreolysis 
purposes. The development of the Ellex laser with Reflex technology specifically 
designed for laser vitreolysis spurred the popularity and implementation of LFT in local 




using the Ellex Q-switched Nd:YAG Tango Reflex Laser, designed for posterior and 
anterior segment viewing31. True Coaxial Illumination (TCI) offers improved 
visualization and illumination throughout the vitreous humor. Surgeons now possess the 
ability to toggle between on-axis and off-axis slit lamp positions for improved spatial 
context within the eye and heightened visualization from the lens to the retina. On-axis 
mode is best utilized for floaters within the middle and posterior vitreous, while off-axis 
mode is recommended for viewing opacities in the anterior vitreous and increasing 
contrast. TCI affords physicians clarity within the three-dimensional space, making it 
easier for physicians to ascertain floater proximity to important structures32. Ellex laser’s 
duo modes offers a complete view of surrounding structures and opacities in relation to 
them, providing the physician with greater visibility33. Ellex’s laser technology may grant 
physicians greater accuracy, potentially decreasing the risk of striking a peripheral 
structure.  
The Ellex laser also boasts a highly efficient laser pulse profile with a non-linear 
energy. The plasma energy beam vaporizes inert collagen fibrils and hyaluron into gas 
that can then be absorbed in the eye without inducing intraocular inflammation. 
Generally, opacities located posteriorly require more energy to vaporize, but physicians 
should start at a low pulse energy then titrate upwards to a maximum of approximately 8-
10mJ33,34. A key feature of Ellex’s Reflex technology is the non-linear relationship 
between pulse energy and the energy dispersion within the eye. Linear increases in laser 
energy settings produce a lesser amount of dispersed energy, resulting in a focused beam 




contributes to both the efficacy and safety of photodisruption. Advanced technology 
grants physicians the tools to offer a safe, effective laser treatment utilizing Ellex lasers.  
The physician first positions the patient securely within the headrest and peers 
through the slit lamp attached to the laserhead and objective lens. The illumination tower 
aligns with the vertical optical axis in the  “on-axis” position and then can be moved 
anteriorly into the “off-axis” position. The illumination tower beams light through the 
direct contact lens on the patient’s eye. Various lenses ranging from CGPL Capsulotomy 
Contact Lens to Ocular Karickhoff 21mm Vitreous Lens can be utilized in laser 
vitreolysis, but the surgeons at BVBL prefer using the VOLK Singh MidVitreous Lens 
designed specifically for laser removal targeting opacities in the central vitreous36. It 
boasts a 1.16x magnification with a 0.86 spot size, resulting in excellent intraocular 
focusing. The lens makes direct contact with the treatment eye necessitating a viscous 
coupling fluid (goniosol) for laser projection. At a height of 24mm, the shorter lens 
allows for greater ease handling the slip lamp and increased range of depth. It should be 
noted that standard Goldmann lenses are not sufficient for vitreolysis37,38.  
Standard treatment spot size is generally fixed at 8 microns with a pulse width of 
4 ns, leaving the amount of energy per pulse and number of shots as variables for 
treatment. The surgeons at BVBL utilized single-shot mode with an average of 300-400 
shots per session and capping each session at a maximum of around 500 shots. They 
operated within the designed “safe zone”, at least 3-4mm from both the crystalline lens 
and retina to avoid unintentional injury. Recommendations instruct the physician to work 




obfuscate the target39. Caution must be taken for floaters near the macula; instruct the 
patient to redirect their gaze in an attempt to relocate the opacity before firing.  
  
An Overview of the Laser Floater Treatment 
In our study, the patient first goes through a series of visual acuity tests in 
addition to an intraocular pressure reading, macular OCT and Optos retinal imaging to 
rule out underlying pathology and for baseline imaging prior to treatment. Patients are 
first evaluated to determine whether they qualify for floater laser treatment. 
Contraindications for LFT are active macular edema, cataract formation, and vitreoretinal 
traction40. Vitreoretinal traction is universally recognized as a disqualifying condition, as 
used in Dr. Shah’s study, due to the abnormally strong junctions between the Muller’s 
cells and the internal limiting membrane21. Disruption to the vitreous humor in 
vitreoretinal traction patients could tug on the retina, triggering an adverse event.  
When a patient presents complaining of floaters, the differential diagnosis usually 
includes PVD, a retinal tear or detachment, or vitreous hemorrhaging. Physicians are 
required to distinguish the innocuous presence of floaters from detrimental pathology 
threatening their vision. Ocular, medical, and family histories are also taken as part of the 
screening to ensure no underlying or suspected pathology confounding results. Screening 
for retinal photopsia, which can present with similar symptomatology, prevents including 
patients with psychosomatic visual deficits, rather selecting patients with visible, 




Operability depends on numerous floater characteristics including appearance, 
location, shape, density, and number of bothersome opacities. Ideal targets for laser 
vitreolysis are cobweb or fibrous floaters with discrete borders in an accessible location 
within the vitreous. Weiss rings are usually included in this category given the classic 
circular shape and distinct fibroglial tissue. Poor targets include wispy or diffuse cloud-
like and amorphous floaters or floaters located near critical eye structures41,42. The 
surgeons at BVBL conduct a fully dilated slit lamp examination to determine the 
patient’s candidacy for LFT. Physicians have a discussion with the patient to set visual 
expectations in terms of treatment benefits to ensure realistic expectations.  
 Repeat treatments are often necessary for patients with residual debris following 
vitreolysis requiring additional pulses to dissipate a dense or large opacity43. In these 
cases, the surgeon will evaluate the patients at their follow-up appointment to determine 
if they qualify as a candidate for repeat treatments. It is crucial to note that progress made 
by previous treatments is reversible, and the physician will discuss with the patient to 
manage visual expectations. Often, the primary factor when deciding whether to continue 
laser treatment is the appearance and location of the remaining floaters. If residual 
opacities are acceptable laser targets, and the patient is motivated, the physician can 
recommend subsequent treatments for greater efficacy44.  
 
Current Treatment Paradigm for Benign Vitreous Floaters 
As discussed, floaters have a wide variety of etiology so their presentation 




ruled out, the vitreous opacities are innocuous and often ignored. Some patients complain 
of floaters that are bothersome to activities of daily living (ADLs) and affect their quality 
of vision either because they are darker, larger, or more centrally located to the visual 
axis. In these cases, the patient can elect to pursue interventional treatment if they feel the 
potential benefit outweighs risk. Current treatment paradigms for symptomatic vitreous 
floaters recommend indefinite observation in most cases and intraocular surgery only in 
the minority of patients reporting severe visual burden secondary to floaters.  
The gold standard procedure to treat vitreous floaters is pars plana vitrectomy 
(PPV), a procedure involving a three-port vitrector inserted into the eye from the sclera at 
pars plana region and removing the opacities manually45. Recently, the creation and 
implementation of a single port Intrector46 offers the same treatment using a more 
portable device. There are numerous techniques to PPV, but all involve the inherent risks 
of undergoing intraocular surgery such as accelerated cataract development due to 
oxygen exposure and an increased risk of a retinal detachment, which is often the most 
concerning complication because if left untreated, can cause blindness47. Studies have 
estimated the incidence of post-vitrectomy retinal detachment to be approximately 
30%48,49 and cataract development at 50-70%48,50,51. Even with Sebag and colleagues 
finding the incidence of cataracts following vitrectomy without PVD induction to be as 
low as 24%13, the risk of removing innocuous opacities rarely justifies undergoing 
surgery. As with any surgical procedure, there is an inherent risk of infection as well as 
increased probability of developing vitreous hemorrhage, macular edema, or glaucoma52. 




procedure involves replacing the vitreous humor with isotonic saline. PPV has a side 
effect profile that necessitates severe visual impairment to warrant undergoing surgery 
and risking vision loss53. Since floaters are not pathological, vitrectomies are only 
indicated if the patient feels their floaters affect their vision significantly enough that the 
benefits of removing the opacities justify the risks of intraocular surgery54–56.  
The floater laser has the potential to offer patients a safer, less invasive alternative 
to vitrectomy that can be performed in-clinic57. While LFT boasts a better side effect 
profile, vitreolysis has been less efficacious at resolving symptoms compared to 
vitrectomy19,58. Floater laser treatment is considered vitreolysis, which, as the name 
suggests, involves the vaporization of opacities without physically removing them. 
Breaking up the collagen tangles allows the immune system to clear the leftover debris, 
but sometimes the fragments can aggregate or persist even after vaporization59. In this 
way, LFT does not replace the role of PPV but can mitigate symptoms that would 
motivate a patient to pursue surgery60. Laser vitreolysis holds merit as a potential 
treatment option for floaters not large or plentiful enough to warrant intraocular access 
while offering better quality of vision61. LFT, if proven efficacious with minimal risk, 







 Vitreous symptomatic floaters frustrate numerous patients in the ophthalmic 
setting, but recommended treatment course is generally observation. PPV offers 
resolution of symptoms with the inherent risks of intraocular surgery including but not 
limited to retinal damage and accelerated cataract development. Several studies have 
been published investigating the efficacy and safety of laser vitreolysis, and the general 
consensus reports moderate symptomatic improvement with a good safety profile21,52,58. 
Analyzing patient satisfaction and visual outcomes of LFT patients offer additional data 
supporting the implementation of laser vitreolysis as an accepted treatment alternative to 
vitrectomy.  
 This retrospective study of Nd:YAG laser vitreolysis outcomes utilized the data of 
patients with complaints of symptomatic floaters at BVBL. 32 patients (32 eyes) were 
treated with Nd:YAG laser vitreolysis over a variable number of sessions, totaling 77 
treatments performed. Objective data including number of treatments each patient needed 
for maximal visual benefit and the proportion of patients who failed vitreolysis then went 
on to pursue secondary PPV. A self-administered survey collected subjective data 
regarding overall quality of vision, frequency and severity of floaters, and impact of their 
floaters on activities of daily life. This study seeks to contribute to the scarce existing 
research on both the efficacy and safety of the floater laser treatment in hopes of 








 This retrospective study of 32 eyes underwent a collective 71 treatments from 
October 2018 through February 2021. Since implementation of the floater laser 
treatment, BVBL has offered this treatment option as an in-office procedure performed 
by Dr. Samir Melki, Dr. Jason Brenner, or Dr. Macie Finkelstein in the Brookline office. 
Eligible patients must be current patients at BVBL, many of who were referred by 
outside clinics for floater evaluation. Initial evaluation included a pupil dilated 
examination, visual acuity (VA) measures, intraocular pressure (IOP) readings, and 
retinal imaging to determine patient candidacy. Subjective data was collected through a 
patient administered survey comparing their quality of vision before and after laser 
vitreolysis. Patients complaining of symptomatic floaters and motivated to pursue floater 
laser treatment were monitored for at least two months to allow time for observation in 
the case of self-resolving floaters. All patients were evaluated for underlying pathology 
and cleared for laser treatment pre-operatively. Demographic data was collected 
including age, sex, ocular history, medical and surgical history, and refractions.  
 
Inclusion Criteria and Contraindications for LFT 
 Patients eligible to be included in the study required an observation period of at 
least 2 months with complaints of symptomatic floaters, etiology ranging from PVD to 




population. Preoperative evaluation included a comprehensive pupil dilated examination 
for the surgeon to visualize the size, density, characteristics, and location of the floater. 
Operable floaters need to be at least 2mm away from the retina and crystalline lens with 
good visualization through slit lamp. Generally, the surgeons’ optimal target opacity will 
be within the middle third of the vitreous humor for phakic patients and anterior two-
thirds for pseudophakic patients. Poor laser targets include very mobile floaters, 
excessively large floaters, and wispy or cloud-like floaters without discrete borders. Thus, 
the surgeon will determine the likelihood of successfully treating the vitreous opacity, 
taking into account appearance, location, and visibility before proceeding with treatment. 
Patients were cleared from a retinal standpoint to rule out underlying pathology that 
would increase risk of a retinal event63. Ocular diseases that serve as a contraindication to 
LFT include vitreomacular traction, active macular edema, and occasionally the presence 
of cataracts64. Depending on the severity of capsule opacification, the surgeon might 
recommend having cataract removal prior to floater laser treatment.  
 Approval for LFT was also contingent on the patient’s vitreous opacities being 
visible through slit lamp examination and during the procedure while positioned at the 
laser. Patients sign consent forms prior to the procedure that ensures they understand and 
accept the risks of LFT including but not limited to retinal detachment, retinal injury, 
accelerated cataract formation, damage to the optic nerve, intraocular inflammation, 
ocular hypertension, hemorrhage and irreversible blindness. Further, patients with ocular 
diseases that are contraindications to LFT were excluded from the study due to increased 




procedure to ensure informed consent. Only one eye was treated for each laser treatment 
session, totaling 32 eyes treated in total.  Patients were also asked to follow-up in the 
clinic approximately 1 month following their laser treatment to ensure no adverse effects.  
 
In-Clinic Procedure 
Vitreolysis was performed using the Ellex Nd:YAG laser as an in-clinic 
procedure at BVBL. The patient first underwent a series of visual acuity tests in addition 
to an intraocular pressure reading, Heidelberg Spectralis macular Optical Coherence 
Tomography (OCT)7 (Heidelberg Engineering, Germany) and Optos22 (Scotland, UK) 
color photography retinal imaging to rule out underlying pathology and for baseline 
imaging prior to treatment.  
Preoperative drops administered to the operative eye included 1% Tropicamide 
and 2.5% Phenylephrine for dilating the pupil, and 0.15% brimonidine tartrate as a 
prophylactic measure to prevent increases in intraocular pressure. Pupil dilation was 
taken for approximately 20-30 minutes or until fully dilated (at least 5 mm) to offer the 
surgeon maximal visualization into the vitreous.  
The Nd:YAG laser was set to single shot mode with pulse energy ranging from 5-
7mJ per pulse, with 7mJ being the maximum pulse energy. The mean number of 
treatment sessions per patient was found to be 2.5 per patient with approximately 300-
400 pulses per session. Floaters located more posteriorly tended to require higher energy 
per pulse to reach. The surgeons verified treatment eye of each patient then used a VOLK 




focus within the vitreous humor. Local anesthetic was administered in the form of 0.5% 
proparacaine eye drops. 
Floater laser patients were required to wait approximately 30 minutes for a 
postoperative IOP check following their procedure. IOP under 25mmHg signifies that the 
patient can monitor their recovery at home. IOP over 25mmHg warrants a final 
evaluation by the doctor and their recommendations for continuing care, usually 
prescribed glaucoma drops for pressure control.  
 Patients who were dissatisfied with their resultant vision were evaluated to pursue 
subsequent laser treatment sessions. Patients enrolled in the LFT BVBL study underwent 
anywhere from 1-6 individual treatment sessions until either the patient reported visual 
satisfaction or the operating physician determined that the patient had maximized visual 
benefit or total pulse energy from collective treatments approaches a dangerously high 
total energy. Visualization of residual opacities is crucial in determining whether further 
treatment would offer any visual benefit. It is also possible to reverse visual benefit 
gained from earlier treatments, so the surgeon must weigh the potential benefit prior to 
recommending further treatment. Generally, the surgeons at BVBL caution against more 
than 3 sessions of vitreolysis per treatment eye. If the surgeon determined that either the 
residual floaters were not operable or the patients’ side effects contraindicated additional 
laser treatment, the surgeon would then recommend observation and coping with 
symptoms or considering vitrectomy.  
 




 Following their procedure, patients returned in approximately 1 month for 
postoperative follow-up and retinal imaging. Data points of interest included number of 
treatments it took for each patient to reach maximal benefit and the number of patients 
who went on to have secondary vitrectomy. Patients who failed vitreolysis or wanted to 
pursue further visual clarity were evaluated for pars plana vitrectomy either within the 
clinic or at an outside institution. Secondary PPV patients serve as a measure of 
vitreolysis failure for persistent symptoms.  
 
Subjective Measures 
History and chief complaints were documented in-clinic prior to and following 
the laser. The patients were administered a 6-question survey comparing quality of vision 
before and after treatment to collect subjective data on patient satisfaction. The three 
subjective measures tested were overall quality of vision, severity/frequency of floaters, 
and impact of floaters on activities of daily life. Overall quality of vision was measured 
on a subjective 4-point scale (Scale 1: rarely noticeable, Scale 2: noticeable a few times a 
week, Scale 3: noticeable every day, Scale 4: noticeable multiple times a day). 
Severity/frequency of floaters were measured on a 4-point scale corresponding to 
whether their floaters were rarely noticeable (Scale 4), noticeable a few times a week 
(Scale 3), noticeable every day (Scale 2), and noticeable multiple times a day (Scale 1). 
Finally, patients were asked to rate their impact the floaters have on activities of daily life 
that include reading, using the computer, driving, and exercise. Answers were again 




week (Scale 3), bothersome everyday (Scale 2), and bothersome multiple times a day 
(Scale 1). Questions were structured to capture both subjective patient satisfaction and 
resultant impact on their quality of life. All questions were asked in the context of before 






Analysis of Study Population 
 Analysis of 32 treatment eyes aimed to capture the efficacy of the laser and 
patient satisfaction with resulting vision. LFT procedures performed within October 2018 
through February 2021 by Dr. Samir Melki, Dr. Jason Brenner, or Dr. Macie Finkelstein 
were analyzed. Patient demographics showed the youngest patient treated was 44 years 
old with a history of ocular trauma, and the oldest being 91 years old with a history of 
PVD. All were required to monitor their symptoms for at least 2 months to determine if 
the smaller, diffuse floaters would self-resolve with observation. One of the thirty-two 
participants (3%) experienced 50% improvement in floater symptoms during this 
observation period, while the other thirty-one (97%) patients reported either consistent or 
worsening symptoms in the interim. Despite minimal resolution during the observation 
period, monitoring symptoms remains the standard of treatment to ensure maximal 
resolution before submitting the patient to the risks of laser intervention.  
 Of the thirty-two patients, fourteen (44%) were treated by Dr. Samir Melki, 
seventeen (53%) were treated by Dr. Jason Brenner, and one (3%) was treated by Dr. 
Macie Finkelstein. Of the seventy-seven total treatments, 42 sessions (55%) were 
performed by Dr. Melki, 33 sessions (43%) performed by Dr. Brenner, and 2 sessions 
(2%) performed by Dr. Finkelstein. All enrolled patients had a preoperative floater 
evaluation during which they met with their surgeon and were informed of their 






Number of Treatments 
 Sample population was analyzed to determine the number of laser sessions each 
patient underwent before discontinuing LFT (Figure 1). Approximately 8 patients (25%) 
of the 32 completed 2 treatment sessions before either gleaming maximum visual benefit 
or deemed too risky to continue. Mean number of sessions when averaged among all 
thirty-two participants was found to be approximately 2.5 sessions per patient. The 
maximum number of sessions performed on one patient was 6 sessions as subsequent 








Figure 1. Number of laser sessions per patient. The number of laser sessions each 
patient underwent ranged from 1 to 6 discrete sessions (N=32) totaling 77 treatments 
conducted in the study. Above figure shows a mean of 2.5 treatments before either 
reaching maximal visual benefit or barred from pursuing further treatment due to safety 
concerns. 
 
Secondary Vitrectomy after Failing Vitreolysis  
Of the 32 patients, 30 (94%) reported some amount of improvement of symptoms 
upon follow-up and have not decided to pursue vitrectomy for further treatment. The 
amount of improvement is quantified in the subjective data collected from the survey. 
Two of the thirty-two (6%) patients reported no improvement or worsening of symptoms 
following the laser and went on to pursue PPV with a retinal specialist as an alternative 
resolution.  
We utilized the number of patients who went on to vitrectomy as a measure of 
ineffective vitreolysis. Of the 2 pursuing secondary vitrectomy, one reported no 
difference in symptoms following the laser, and one reported exacerbated symptoms due 
to large floaters fractionated into smaller, numerous diffuse ones.  
 
Patient Satisfaction 
 To quantify improvement, subjective data was collected through a self-
administered survey comparing three visual clarity measures (overall quality of vision, 




treatment. Fifteen (46.9 %) of the thirty-two participants responded to the survey, and 
their responses were analyzed to determine patient satisfaction. The survey asked 
participants to rate the overall quality of vision before and after the laser treatment on a 4-
point graded scale (Scale 1: poor, Scale 2: moderate, Scale 3: good, Scale 4: great). Prior 
to treatments, 4 of 15 (26.7%) participants reported poor quality of vision (Scale 1), 8 of 
15 (53.3%) reported poor to moderate quality of vision (Scale 2), and 4 of 15 (20.0%) 
reported moderate to good quality of vision (Scale 3) with zero patients reporting great 
quality of vision (Scale 4). Following treatment, 5 of 15 (33.3%) reported great quality of 
vision (Scale 4), 6 of 15 (40%) reported moderate to good quality of vision (Scale 3), and 
4 of 15 (26.7%) reported poor to moderate quality of vision (Scale 2) with zero patients 
reporting poor vision (Scale 1) (Figure 2). When averaged among all 15 subjective 
responses, patients who responded to the survey reported a mean improvement of +1.13 
in the 4-point scale rating overall quality of vision. Thus, survey responses reinforce the 
potential benefit for laser treatment given the mean suggests an overall positive 




 Quality of vision prior to and following LFT 
 
Figure 2: Quality of vision prior to and following LFT. A self-administered survey 
inquired about overall quality of vision prior to LFT and following LFT. Following 
treatment, Scale 1 (poor quality of vision) and Scale 2 (moderate quality of vision) are 
reduced and Scale 3 (good quality of vision) and Scale 4 (great quality of vision) are 
increased when compared to pre-treatment scales. 
 
The survey also investigated the severity and frequency of floaters before and 
after LFT. Participants reported an average +1.00 improvement in severity and frequency 
on a 4-point scale (Scale 1: rarely noticeable, Scale 2: noticeable a few times a week, 




15 patients who responded purported no difference in severity and frequency of 
symptomatic floaters. All 15 pretreatment responses fell into either Scale 3 or Scale 4, 
with 11 (73%) of 15 patients saying their floaters are noticeable multiple times a day. 
Post-treatment responses ranged among all four scales, but the largest changes lie in 
Scale 4, initially representing the severity/frequency of floaters for 73% of participants. 
Following LFT, only 4 (27%) of 15 participants chose Scale 4 compared to 73% prior to 
vitreolysis (Figure 3). Thus, the 46% improvement seen in Scale 4 regarding the 
frequency and severity of floaters offers promising data regarding the potential for 
vitreolysis to mitigate severe symptomatology.  
 
 
Figure 3: Severity/Frequency of floaters prior to and following LFT. The largest 
improvement in severity/frequency of floaters is seen in Scale 4 (noticeable multiple 
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prior to treatment to 4 patients reporting the same frequency and severity after vitreolysis. 
Scale 1 (rarely noticeable) and Scale 2 (noticeable a few times a week) both increased 
following laser treatment.  
 
 
The final subjective measure tested on the administered survey attempted to 
capture the visual and psychological burden of the patients’ symptomatic floaters on their 
daily lives including the impact on near and distance vision activities. Patients reported 
an average improvement of +1.33 on a 4-point scale (Scale 1: rarely bothersome, Scale 2: 
bothersome a few times a week, Scale 3: bothersome every day, Scale 4: bothersome 
multiple times a day). 4 (26.7%) of the 15 patients reported no change in the impact their 
floaters have on their quality of life (Figure 4). While all 15 patients chose either Scale 3 
or Scale 4 prior to LFT, 8 (53%) of 15 patients chose either Scale 2 or Scale 1 following 
LFT. The clear shift in patient responses trending towards improvement offers promising 
data regarding the efficacy of vitreolysis on improving symptomatic floaters.  
While all measures showed an average positive improvement in symptoms, the 
largest increase in averaged values assigned a 4-point value scale is seen in the question 
investigating the impact of floaters on activities of daily living. 3 (20%) of the 15 patients 
reported that while the severity and frequency of their floaters did not change, the impact 
the existing floaters have had on their lives improved by one scaled point, reinforcing the 
multifactorial nature of the effect of floaters on patient wellbeing. Our findings suggest 
LFT can offer moderate improvements in overall quality of vision (+1.13), severity and 





Figure 4: Impact of floaters on activities of daily living prior to and following LFT. 
All 15 patients reported either Scale 3 (bothersome every day) or Scale 4 (bothersome 
multiple times a day) prior to LFT. Following LFT, 8 patients showed improvement 





 Of the thirty-two patients treated in this study, 4 patients (12.5%) had adverse 
events either during or following the floater laser treatment. The adverse events included 
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One patient had a retinal injury occur during their fourth session due to a sudden 
movement of the patient’s head positioned in the laser. At their follow-up appointment, 
the retinal specialist found a small retinal impact with a temporal scar. OptosAdvance 
imaging shows the retinal hole in relation to the macula and optic nerve indicated by the 
arrow in Figure 5. There was no evidence of developing choroidal neovascular membrane 
(CNVM). The patients’ visual acuity remained the same pre and postoperatively with a 
bilateral distance VA of 20/40 sans correction before and after laser treatment. In light of 
this incident, additional precautions such as a head strap and secure positioning at the 
laser would decrease the likelihood of a repeat incident. LFT outcomes are heavily 
dependent on physician accuracy, thus reinforcing the importance of appropriate 







Figure 5: OptosAdvance image of an intraoperative retinal hole. (A) OptosAdvance 
image of the left fundus showing an intraoperative laser impact to the retina indicated by 
the arrow. The retinal hole is shown in a close-up image with increased contrast for 
improved visibility. Note the distinct retinal hole indicated by an arrow appearing red as a 
result of increased visibility of the choroid capillaries seen in the enlarged macular area 









 The second patient experienced retinal trauma during the second laser session 
due to erroneous aim of the laser pulse. These incidents can be attributed to human error, 
which is possible despite extensive training given that the surgeon is aiming at a moving 
target, often without discrete borders. The retinal specialist examined the patient the 
following day and found a stable sub-RPE retinal hemorrhage with no operculum. Figure 
6 shows an OptosAdvance image taken on the day of the LFT using the autofluorescence 
(AF) setting with an arrow indicating the retinal hemorrhage from the laser. AF color was 
applied for greater contrast of darker regions that indicate retinal pigmented epithelial 
(RPE) damage68. This type of retinal hemorrhage, if no macular involvement, usually has 







Figure 6. OptosAdvance AF image of the retinal hemorrhage. The OptosAdvance 
image shows the retinal hemorrhage from the LFT in this patient (see other examination 
results of this patient in Figures 7-9). Autofluorescence indicates damage to the RPE with 
a darker grey, seemingly opaque from the sub-RPE hemorrhage from the laser.  
 
Immediately following the procedure, the patient complained of a dark spot in his 
field of vision and completed a 24-2 Swedish Interactive Thresholding Algorithm (SITA) 
full-threshold Humphrey Visual Field (HVF) test to document the deficit. The test is 
scored by the decibel (dB) graph with the values ranging from 0-50 dB with 30 dB being 
the mean score in normal visual field. A value of 0 means the patient did not see the 
brightest targets and 50 meaning the dimmest target was seen. The grey-scale graph 
provides a visual interpretation of the data, with the light areas corresponding to higher 
decibels and darker areas indicating lower decibels and the presence of a visual deficit. 
Figure 6 shows the patient’s visual field immediately following LFT with a scotoma, or a 
spot of diminished vision in a visual field, in the upper right quadrant. In the area of the 
deficit, the lowest value was 2 dB, indicating a clear visual loss69. The patient was sent 
home with a 1-month course of Durezol, Bromfenac, and lutein eye drops and an Amsler 
grid daily check. At his 10-day follow-up, the patient reported improvement in the visual 
deficit and his symptomatic floaters, and at his 1-month appointment, the patient reported 
complete resolution of the visual defect. 24-2 SITA HVF tests and macular OCT images 
were repeated at his 10-day and 1-month follow-up to document the patient’s progress. 




respectively. The scotoma is resolved in both HVF results, a positive prognosis seeing 
resolution in two consecutive visual field tests. The patient currently reports no residual 
deficits from the retinal hemorrhage. 	
 
Figure 7. 24-2 SITA HVF following LFT revealing a scotoma. Visual field test of the 
retinal hemorrhage of this patient (See Figure 6) indicates an abnormal score of 2 dB in 
the upper right quadrant of the decibel graph. Deviation graphs show the patient’s score 
relative to a “normal” field graph, with a -31 score associated with the scotoma. The 
grey-scale map offers a visual depiction of the data with the dark shaded area 








Figure 8. Repeat 24-2 SITA HVF at 10-day and 1-month follow-ups. Visual field tests 
from the 10-day follow-up (A) and the 1-month follow-up (B) of the same patient as 
Figures 6-7 indicate decibel scores consistent with a normal visual field. The grey-scale 
map indicates a normal upper right quadrant along with a decibel graph confirming 
resolution of the scotoma. These test results are consistent with the patient’s subjective 













Figure 9. Macular OCT images: Day of LFT, 10-day, and 1-month follow-up. 
Macular OCT images from the patient in Figures 6-8 taken on the day of the retinal injury 
(A) shows the region of damage to the retinal layers evident in the white hues 
corresponding to the hemorrhage. Optos images of the 10-day (B) and 1-month follow-up 





Following the laser floater treatment, the patient suffered the loss of a portion of 
his vision secondary to the retinal hemorrhage for several days before resolution of 
symptoms. He was successfully treated with a combination therapy of corticosteroid and 
non-steroidal anti-inflammatory eye drops. At subsequent visits, the patient reported no 
residual deficits in his vision and his corrected visual acuity remained 20/20 before the 
laser treatment and after the 1-month follow-up. The patient does report some 
improvement in symptomatic floaters, and he has not decided to pursue PPV.  
 
Cystoid Macular Edema 
 A LFT patient developed cystoid macular edema following the procedure, as seen 
on repeat macular OCT images. Cystoid macular edema (CME) involves fluid cysts 
developing in the macula. CME is commonly caused by either inflammation related 
etiology or vitreous traction and can often be treated pharmacologically or surgically 
before irreversible damage occurs70,71. This patient developed acute CME following the 
laser floater treatment as seen on macular OCT imaging taken at the patient’s follow-up 
appointment (Figure 10). The thickness map shows swelling at the macula, corresponding 
to the edematous cysts accumulating within the retinal layers. The patient had no visual 
complaints secondary to the CME and was successfully treated pharmacologically with a 
1-week course of anti-inflammatory eye drops. At a later follow-up appointment 
following drop therapy, the patient’s repeat macular OCT showed dramatic improvement 




map values show the greatest improvement following treatment, with a volume of 0.32 
mm3 immediately following LFT compared to a volume of 0.29 mm3 one week later. The 
patient had preserved visual acuity (corrected to 20/20) prior to and following vitreolysis 
and reported no symptomatic complaints secondary to the CME. 	
 
Figure 10: Macular OCT Images: Cystoid Macular Edema. OCT image of the right 
eye of one patient immediately following LFT. Note the fluid filled cysts collecting in the 






Figure 11: Macular OCT Images: Cystoid Macular Edema, Treated. OCT image of 
the right eye of the same patient as in Figure 10 shows that after successful 
pharmacological treatment, drastic improvement in the edema is reflected in the central 
thickness value decreasing to 0.29 mm3 from 0.32mm3 as shown above.  
 




 One patient experienced accelerated cataract development following his two 
treatment sessions. This patient returned to the clinic complaining of increasingly cloudy 
vision specifically in the treatment eye. The operating surgeon hit the crystalline lens 
during the procedure, and accelerated opacification occurred in the study eye in the two 
months following the procedure. In this case, the posterior capsule opacification proved 






Number of Treatment Sessions 
Our study aimed to investigate the full efficacy of Nd: YAG laser vitreolysis and 
thus allowed for multiple discrete laser sessions per patient. Patient candidacy for further 
treatment involved a physician mediated decision based on the potential visual benefit 
from treating remaining floaters. Discontinuation of laser floater treatment meant either 
the patient reached full visual benefit or the physician felt subsequent treatments would 
be detrimental. When averaged among participants, our study found a mean of 2.5 
sessions per patient. While our results were promising regarding the efficacy of multiple 
laser sessions, there exists a need for further research into the number of treatment 
sessions as a variable affecting overall efficacy. Existing literature primarily investigates 
single treatment session outcomes, thus highlighting the need to explore how numerous 
discrete treatments can affect the patient. 
Dr. Shah and his colleagues published the first randomized controlled trial (RCT) 
investigating outcomes of Nd:YAG laser vitreolysis when compared to a control group 
given a sham procedure simulated with the laser off. His team found moderate 
improvement in symptoms for the experimental group who underwent YAG laser 
treatment, approximately 53% of participants reported significantly improved or resolved 
symptoms whereas zero participants in the control group reported any improvement. 





Despite executing the first RCT investigating vitreolysis outcomes, the study had 
several limitations that should be addressed. Their study capped the number of treatments 
to one session per patient, thus limiting the potential visual benefit the patient could have 
received from a single session. According to Shah’s team, adding subsequent sessions to 
the RCT would compromise the confidentiality of the sham group, thus deciding on a 
single laser treatment per patient21. BVBL surgeons wanted to analyze vitreolysis 
outcomes in real patient populations, allowing for multiple sessions to provide maximal 
visual benefit.  
 Due to the difference in methodology between BVBL patients and those analyzed 
in Dr. Shah’ study, it is inaccurate to compare findings of adverse events between the two 
populations. While Dr. Shah’s study boasts a good safety profile, the total pulse energy 
applied to the vitreous increases linearly with each subsequent session thus increasing the 
risk of an adverse event occurring21. As such, the RCT holds value in promoting the 
efficacy of a single LFT but fails to adequately capture the true side effect profile of a 
real patient seeking symptomatic resolution. Further research should be conducted to 
determine how varying the number of treatment sessions can affect both efficacy and 
safety of YAG vitreolysis72. 
 
Secondary Vitrectomy after Failing Vitreolysis 
Vitrectomy varies widely in technique depending on the gauge and ports utilized, 
but the basic procedure involves the surgical removal of the vitreous humor. As such, any 




resolution of symptoms.  Vitreolysis has yet to rival the success rate reported from 
numerous studies on vitrectomy outcomes. De Nie and team found approximately 85% of 
the 110 patients who underwent PPV reported to be satisfied or very satisfied with this 
vision73. Dr. Sebag’s one study analyzed 195 eyes treated with vitrectomy and found an 
improvement in vitreous echodensity and visual acuity following surgery74.  
For the 30 BVBL patients who did not pursue PPV following LFT, their 
symptoms were at least partially mitigated compared to baseline. Even though 
vaporization of vitreous floaters does not promise complete resolution, it can alleviate or 
delay symptomatic floaters from reaching a point of dysfunction severe enough to justify 
surgical intervention75. In this way, vitreolysis offers a potential treatment to fill the 
treatment gap between observation and intraocular surgery.  
 
Patient Satisfaction 
Vitreolysis, in its ability to fractionate and vaporize opacities, can actually 
improve overall quality of vision and the psychological impact these floaters have 
without removing the opacity itself. A similar study performed in Korea under Dr. Kim 
found that vitreous floaters have a profound and substantial psychological impact on 
afflicted patients when compared to the control group26. Practicing ophthalmologists can 
attest to this finding given how some patients report seeming disproportionate 
dysfunction secondary to vitreous opacities18.  
Data from the BVBL study suggests similar conclusions regarding the ability of 




Self-administered patient surveys revealed an average positive improvement in symptoms 
in all three tested measures. However, the largest increase in averaged values is seen in 
the question investigating the impact of floaters on activities of daily living. 3 (20%) of 
the 15 patients reported that while the severity/frequency of their floaters were 
unchanged, the impact the existing floaters have had on their lives improved by one 
scaled point, reinforcing the value of laser vitreolysis as a potential solution to 
bothersome floaters. 
Patient burden is arguably the most difficult variable to measure given the 
subjective complaints of patients and the varying effect each floater has on the field of 
vision. Wagle and team attempted to quantify this burden using SG; results suggested 
despite duration of floater complaints patients were consistently bothered with no 
evidence of neuroadaptation from any of the participants. They compared the burden of 
vitreous floaters to other diseases such as HIV, diabetes, and hypertension and found 
patients reported a higher risk tolerance to vitreous floaters than the listed chronic 
diseases8. Further evaluation is required to determine whether the study included a 
representative population and thus produced a generalizable finding, but the evidence of 
dysfunction secondary to floaters is irrefutable. At the American Academy of 
Ophthalmology (AAO) 2017 conference, Dr. Paul Inder Singh along with Dr. Chirag 
Shah, Dr. Michael Tibbetts, Dr. Ivan Mac and Dr. Karl Stonecipher discussed the merits 
of floater laser treatment and the potential for widespread use. All speakers attested to the 
numerous patients whose floater complaints were previously dismissed, and how ecstatic 




Vitreolysis “success” must include subjective data to fully encapsulate the 
physical and psychological benefits of floater removal and further research should be 
conducted to capture the multifactorial disease manifestation. Existing data reporting on 
successful vitreolysis is still limited and somewhat contradictory. One study claimed that 
75% of the 30 participants experienced significant improvement while the other 25% 
reported moderate improvement in symptoms76. Tsai and colleagues reported similar 
success claiming that all 15 participants reported high patient satisfaction and improved 
symptomatology. However, current literature regarding vitreolysis efficacy still remains 
contradictory. In a single-center, randomized sham-controlled study 54% of patients 
treated with YAG laser reported diminished symptoms compared to 9% in the sham-
control group21. These findings echoed those of Delaney and team who found varied 
responses to laser vitreolysis. Out of the 39 eyes treated, only 2.5% of cases reported the 
treatment to be significantly beneficial, defined as 50-70% benefit compared to 
baseline77. The range of reported outcomes serves to reinforce the importance of 
additional research to accurately determine the potential benefit of laser vitreolysis.  
 
Adverse Events and the Safety Profile of LFT 
1 patient enrolled in the BVBL study experienced accelerated cataract 
development following LFT, comprising 3% of the total sample population. Thus, it is 
imperative to understand the connection between laser floater treatment and the potential 
for capsule opacification. A study investigating Nd:YAG vitreolysis outcomes of a 




crystalline lens78. Sun and affiliates submitted a case report following a patient who 
experienced rapid cataract progression following Nd:YAG vitreolysis with a best 
corrected visual acuity (BCVA) of 20/1000. After cataract surgery, vision was restored to 
BCVA of 20/2079. In the event of capsule opacification without retinal injury following 
laser treatment, cataract surgery has the potential to again restore visual clarity.  
 Our study resulted in two retinal impacts, postoperative cystoid macular edema, 
and accelerated capsule opacification. However, numerous vitreolysis studies have been 
conducted using retrospective data from local ophthalmology clinics that suggest 
vitreolysis has a good safety profile. Tsai and colleagues published the first YAG laser 
vitreolysis article with high patient satisfaction and no intraoperative or postoperative 
complications for a year after treatment76. Similarly, Dr. Shah’s RCT study found that 
there was no difference in adverse events between the YAG laser treated experimental 
group and the sham laser control group21. A study conducted at Chongqing General 
Hospital echoed claims of safety after 30 patients underwent vitreolysis with no 
statistically significant differences in VA, IOP, and retinal nerve fiber layer (RNFL) 
thickness surrounding the optic nerve before and up to 6 months following laser 
treatment76. Delaney and team found similar outcomes in their sample population, 
following patients for 15 months without a single complication or incident80. Consistency 
among safety profiles conducted by different investigators is promising for the 
implementation of vitreolysis, but there is little evidence on long-term complications as 




safety profile of vitreolysis remains incomplete without additional prospective studies to 
determine long-term consequences of photodisruption to the vitreous. 
Our patient outcomes offer data on the efficacy of Nd:YAG laser vitreolysis as 
measured by self-administered questions following quality of vision, frequency and 
severity of floaters, and impact on ADLs. Analysis of collected data regarding patient 
satisfaction, number of sessions and overall efficacy of treatment supports the conclusion 
that LFT is an efficacious, safe procedure for symptomatic vitreous floaters. Additional 
studies offer insight into the potential role of vitreolysis as a less invasive alternative to 
PPV and a more robust treatment than observation.  
 
Efficacy of the Laser Floater Treatment 
All three measures showed a median positive improvement in symptomatology by 
a minimum of +1.00 on a 4-point scale attempting to quantify visual clarity. Impact of 
vitreous floaters on patients’ quality of life yielded the highest statistical improvement, 
approximately a 33% (+1.33/4) improvement in visual burden on activities following 
laser fractionation. Existing literature shows varied subjective and objective measures 
attempting to capture visual burden and ranging from a self-administered questionnaire to 
a contrast sensitivity test. The challenge lies in quantifying “success” in vitreolysis 
because patient outcomes range so widely and rely on subjective measures to fully 
capture the physiological burden. Shah utilized a visual disturbance score on a 0-100% 
scale and a 5-point qualitative scale they developed whereas Delaney employed a similar 




Our study utilized a 4-point scale for each of the 6 questions comparing different aspects 
of vision before and after treatment in an attempt to capture the multifactorial burden of 
vitreous floaters. In addition, each vitreolysis study used different inclusion criteria; Shah 
only recruited patients with a history of PVD and selected Weiss rings, which are good 
operable targets whereas Delaney also included patients with vitreous myopathy 
presenting with various floaters21,80. The inclusion criteria utilized in this study recruited 
patients with floaters of various frequency and appearance and completed numerous 
sessions to offer maximal visual benefit.  
Subjective data collected regarding patient satisfaction bolsters the argument for 
LFT implementation as a treatment option less invasive and less effective than vitrectomy 
but more invasive and more effective than observation alone. 4 patients (27%) of 15 
reported poor overall quality of vision (Scale 1) prior to the laser treatment with 0% 
touting great overall vision (Scale 4). Following the floater laser, 5 (33%) of 15 reported 
great quality of vision (Scale 4) with 0% reporting poor overall vision (Scale 1) with 
treatment. It is crucial to recognize that there may be attrition bias due to the incomplete 
responses from all participants and motivated, satisfied patients are more likely to offer 
their input than moderately affected patients. Thus, further research should be conducted 
to determine the true efficacy of laser vitreolysis.  
 
Limitations of Objective Measures  
 This study is primarily limited in terms of objective data collected for each 




treatment to determine visual acuity changes as a result of vitreolysis. While our study 
investigated subjective measures of visual quality, objective data such as VA would 
provide data using a standard ophthalmic measurement for quantifying vision. Patients 
reporting improved overall quality of vision might show objective improvements in their 
visual acuity, supporting the efficacy of laser vitreolysis. Collecting VA could also 
provide valuable data on visual impairment resulting from adverse events during LFT. 
Future studies should include this measure in data collection to bolster the validity of the 
study.  
 
 Limitations of Subjective Measures 
 Additional studies should be conducted regarding the subjective efficacy of the 
floater laser. While a coded 4-point scale offers quantifiable symptomatic improvement, 
outside studies have used varied measures attempting to capture the full dysfunction 
caused by floaters. The challenge remains finding a comprehensive report from the 
patient perspective on the efficacy of the laser treatment. Patient satisfaction will play a 
crucial role in the establishment of LFT as an efficacious alternative to surgery. 
 
Implications for Future Research  
The BVBL study analyzed patient outcomes using measures of visual satisfaction 
along with the number of Nd: YAG floater laser sessions per treatment and proportion of 
patients who sought out secondary vitrectomy. Our results concluded that on average, 
patients reported a positive improvement in symptomatic floaters, as seen across all three 
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subjective measures (overall quality of vision, frequency/severity of floaters, and impact 
of floaters on ADLs). Existing literature offers promising potential for the floater laser as 
a treatment with outcomes of varying success in resolving symptomatic floaters58,81. The 
Cochrane Review analyzed existing literature regarding Nd:YAG laser treatment found 
zero studies that conducted a RCT directly comparing vitreolysis with vitrectomy in 
terms of safety and efficacy82. Thus, there is a need to directly compare two different 
treatments for the resolution of symptomatic floaters to determine the true merit of LFT.  
Laser vitreolysis circumvents the need for intraocular access, making LFT an 
appealing option for patients who are only moderately afflicted by their symptoms and 
would otherwise not pursue PPV. However, follow-up data in existing studies is limited 
beyond 12 months and long-term effects of photo disruption after numerous sessions 
should be investigated. Current studies regarding patient outcomes following laser 
vitreolysis present a wide range of success in resolving symptoms. The lack of evidence 
comparing vitreolysis and vitrectomy warrants further investigation for the treatment of 
vitreous opacities including where laser floater treatment fits into that paradigm.  
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